KLISBio Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$15.7M
- Investors
-
13
KLISBio General Information
Description
Developer of an innovative medical technology designed to find new tissue regeneration methods. The company's technology offers silk-based bio-materials that help to regenerate human tissues, including those present in the vascular system, and then to degrade and be safely absorbed in the body, enabling medical research companies to develop products harnessing the power of nano-fibers and use them for the treatment of tissue-related diseases.
Contact Information
Website
www.klis.bioCorporate Office
- Via Ludovico Ariosto, 21
- Bresso
- 20091 Milan
- Italy
Corporate Office
- Via Ludovico Ariosto, 21
- Bresso
- 20091 Milan
- Italy
KLISBio Timeline
KLISBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Jan-2025 | $15.7M | Completed | Generating Revenue | ||
| 8. Grant | 08-Nov-2023 | Completed | Startup | |||
| 7. Later Stage VC | 31-Dec-2022 | Completed | Startup | |||
| 6. Early Stage VC (Series A) | 21-Apr-2016 | Completed | Startup | |||
| 5. Seed Round | 11-Dec-2015 | Completed | Startup | |||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Grant | 05-Aug-2015 | Completed | Startup | |||
| 2. Grant | 05-Dec-2014 | $31.1K | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
KLISBio Patents
KLISBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3227954-A1 | Biomimetic peptides and their use in bone regeneration | Pending | 09-Aug-2021 | ||
| US-20250129123-A1 | Biomimetic peptides and their use in bone regeneration | Pending | 09-Aug-2021 | ||
| WO-2023016904-A1 | Biomimetic peptides and their use in bone regeneration | Inactive | 09-Aug-2021 | ||
| AU-2018248085-A1 | Nanofibers comprising fibroin as well as system comprising hydrogel and said nanofibers | Inactive | 04-Apr-2017 | ||
| EP-3607117-A1 | Nanofibers comprising fibroin as well as system comprising hydrogel and said nanofibers | Inactive | 04-Apr-2017 | D01D5/003 |
KLISBio Signals
KLISBio Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Primo Capital (Milano) | Venture Capital | Minority | ||
| Tech and Biomedical Foundation | Venture Capital | Minority | ||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| Anya Capital | Venture Capital | Minority |
KLISBio FAQs
-
When was KLISBio founded?
KLISBio was founded in 2014.
-
Where is KLISBio headquartered?
KLISBio is headquartered in Milan, Italy.
-
What is the size of KLISBio?
KLISBio has 21 total employees.
-
What industry is KLISBio in?
KLISBio’s primary industry is Therapeutic Devices.
-
Is KLISBio a private or public company?
KLISBio is a Private company.
-
What is KLISBio’s current revenue?
The current revenue for KLISBio is .
-
How much funding has KLISBio raised over time?
KLISBio has raised $27.3M.
-
Who are KLISBio’s investors?
CDP Venture Capital (Rome), Primo Capital (Milano), Tech and Biomedical Foundation, European Innovation Council, and Anya Capital are 5 of 13 investors who have invested in KLISBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process